<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096234</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-56655</org_study_id>
    <secondary_id>CCT5038</secondary_id>
    <nct_id>NCT05096234</nct_id>
  </id_info>
  <brief_title>18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma</brief_title>
  <official_title>Pilot Study of [18F]F-AraG PET Imaging to Evaluate Immunological Response to Chimeric Antigen Receptor (CAR) T Cell Therapy in Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CellSight Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive&#xD;
      commercial or research CAR T cell therapy as anticancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      * Explore the relationship of change in [18F]F-AraG PET signal following CAR T cell treatment&#xD;
      with changes in T cell infiltration in tumor biopsies.&#xD;
&#xD;
      Exploratory Analyses:&#xD;
&#xD;
        -  Explore the relationship of change in [18F]F-AraG PET signal in tumor lesions following&#xD;
           CAR T cell treatment with clinical benefit rate (defined as Complete Response (CR) +&#xD;
           Partial Response (PR) + stable disease (SD) ≥ 3 months) using RECISTv1.1 criteria&#xD;
&#xD;
        -  Correlate the change in [18F]F-AraG PET signal in tumor lesions following CAR T cell&#xD;
           therapy with maximum grade of Cytokine Release Syndrome (CRS) and neurotoxicity&#xD;
           experienced.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measure</measure>
    <time_frame>values obtained on Day 0 and Day 4 (± 2 days)</time_frame>
    <description>Spearman correlation between changes in SUV in [18F]F-AraG signal on PET imaging to changes in T-cell infiltrates in biopsy samples</description>
  </primary_outcome>
  <other_outcome>
    <measure>First exploratory outcome measure</measure>
    <time_frame>≥ 3 months</time_frame>
    <description>correlation between changes in SUV [18F]F-AraG signal on PET imaging to the observed clinical benefit rate using RECISTv1.1 criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Second exploratory outcome measure</measure>
    <time_frame>≥ 3 months</time_frame>
    <description>Correlation between changes in [18F]F-AraG signal to the frequency and grade of two common CAR T cell toxicities, cytokine release syndrome (CRS) and neurotoxicity, if observed in this study population.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>[18F]F-AraG PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo PET imaging at the following time points:&#xD;
Baseline, prior to lymphodepleting chemotherapy: [18F]F-AraGPET/CT, followed the next day by FDG-PET/CT&#xD;
At peak CAR expansion: Day 4 (± 2 days) post-CAR infusion:&#xD;
[18F]F-AraG PET&#xD;
At Day +28 (± 4 days) post-CAR infusion: FDG-PET/CT Subjects will have a paired biopsy after each imaging time point, if possible. Subjects will be followed for safety of [18F]F-AraG for 30 days after last dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[ 18F]F-AraG PET</intervention_name>
    <description>Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)</description>
    <arm_group_label>[18F]F-AraG PET</arm_group_label>
    <other_name>[ 18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D- arabinofuranosylguanine; trade name VisAcT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Histologically confirmed aggressive B cell NHL including the following types defined&#xD;
             by WHO 2008:&#xD;
&#xD;
               -  DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma;&#xD;
                  DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of&#xD;
                  the elderly; OR&#xD;
&#xD;
               -  primary mediastinal (thymic) large B cell lymphoma&#xD;
&#xD;
               -  transformation of follicular lymphoma, marginal zone lymphoma or chronic&#xD;
                  lymphocytic leukemia to DLBCL will also be included&#xD;
&#xD;
          -  Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the&#xD;
             following criteria:&#xD;
&#xD;
               -  At least one measureable lesion away from head &amp; neck, liver, kidneys, GI tract&#xD;
                  and bladder&#xD;
&#xD;
               -  At least one biopsy-accessible lesion or lymph node.&#xD;
&#xD;
          -  Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible&#xD;
             lesion or lymph node.&#xD;
&#xD;
          -  Scheduled to receive commercial or research CAR T cell therapy with axicabtagene&#xD;
             ciloleucel (Yescarta ®) as part of anticancer therapy.&#xD;
&#xD;
          -  Adequate renal and hepatic function, defined as:&#xD;
&#xD;
               1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr &lt; 1.6&#xD;
                  mg/dL&#xD;
&#xD;
               2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome&#xD;
&#xD;
          -  Able to give informed consent. Subjects unable to give informed consent will not be&#xD;
             eligible for this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Subjects with significant GI disease involvement by PET imaging&#xD;
&#xD;
          -  In the investigator's judgment, have any medical condition likely to interfere with&#xD;
             assessment of safety or efficacy, be unable to tolerate additional radiation, or be&#xD;
             unlikely to complete all protocol-required visits and procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Miklos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Iglesias</last_name>
    <phone>650-723-4247</phone>
    <email>mariaigl@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Iglesias</last_name>
      <email>mariaigl@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>David Miklos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>David Miklos</investigator_full_name>
    <investigator_title>Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

